410 related articles for article (PubMed ID: 32139317)
1. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
2. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
3. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
4. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
5. Human sialoglycan ligands for immune inhibitory Siglecs.
Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
[TBL] [Abstract][Full Text] [Related]
6. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.
Läubli H; Varki A
Cell Mol Life Sci; 2020 Feb; 77(4):593-605. PubMed ID: 31485715
[TBL] [Abstract][Full Text] [Related]
8. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
10. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
11. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates.
Padler-Karavani V; Hurtado-Ziola N; Chang YC; Sonnenburg JL; Ronaghy A; Yu H; Verhagen A; Nizet V; Chen X; Varki N; Varki A; Angata T
FASEB J; 2014 Mar; 28(3):1280-93. PubMed ID: 24308974
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
13. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
[TBL] [Abstract][Full Text] [Related]
14. Advances in understanding and exploiting Siglec-glycan interactions.
Jame-Chenarboo Z; Gray TE; Macauley MS
Curr Opin Chem Biol; 2024 Jun; 80():102454. PubMed ID: 38631213
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
16. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
17. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
18. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
19. Regulation of prognosis-related Siglecs in the glioma microenvironment.
Mao R; Zhou L; Yang Y; Wang P; Lin H; Zheng J; Lv G; Zhou D
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3343-3357. PubMed ID: 34472004
[TBL] [Abstract][Full Text] [Related]
20. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.
Wielgat P; Rogowski K; Niemirowicz-Laskowska K; Car H
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]